China SXT Pharmaceuticals, Inc. (SXTC)
NASDAQ: SXTC · Real-Time Price · USD
1.700
+0.140 (8.97%)
At close: Aug 1, 2025, 4:00 PM
1.690
-0.010 (-0.59%)
After-hours: Aug 1, 2025, 4:39 PM EDT
China SXT Pharmaceuticals Revenue
China SXT Pharmaceuticals had revenue of $829.49K in the half year ending September 30, 2024, a decrease of -31.35%. This brings the company's revenue in the last twelve months to $1.82M, up 6.78% year-over-year. In the fiscal year ending March 31, 2024, China SXT Pharmaceuticals had annual revenue of $1.93M, down -2.19%.
Revenue (ttm)
$1.82M
Revenue Growth
+6.78%
P/S Ratio
1.39
Revenue / Employee
$23,212
Employees
75
Market Cap
197.25M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 1.93M | -43.18K | -2.19% |
| Mar 31, 2023 | 1.97M | -630.60K | -24.23% |
| Mar 31, 2022 | 2.60M | -2.18M | -45.53% |
| Mar 31, 2021 | 4.78M | -384.70K | -7.45% |
| Mar 31, 2020 | 5.16M | -1.85M | -26.38% |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
SXTC News
- 4 months ago - China SXT Pharmaceuticals Has Regained Compliance with Nasdaq's Minimum Bid Price Deficiency - GlobeNewsWire
- 5 months ago - China SXT Pharmaceuticals, Inc. Announces Share Consolidation - GlobeNewsWire
- 10 months ago - China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency - GlobeNewsWire
- 1 year ago - China SXT Pharmaceuticals, Inc. Regained Compliance with Nasdaq's Minimum Bid Price Rule - GlobeNewsWire
- 1 year ago - China SXT Pharmaceuticals Announces One-for-Twenty-five Reverse Stock Split - GlobeNewsWire
- 3 years ago - China SXT Pharmaceuticals, Inc. Announces 1 for 20 Reverse Share Split - GlobeNewsWire
- 3 years ago - China SXT Pharmaceuticals, Inc. Enters into Securities Purchase Agreement to Issue a 6% Convertible Promissory Note in the Original Principal Amount of $2.8 Million - GlobeNewsWire
- 3 years ago - Aegis Capital Corp. Acted as Sole Bookrunner on a $4.1 Million Underwritten Public Offering of Ordinary Shares, Inclusive of the Over-Allotment, for China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC). - Accesswire